dx.doi.org/10.3324/haematol.2019.240374, hdl.handle.net/1765/133988
Department of Hematology

Zweegman, S, Stege, C.A.M., Haukas, E, Schjesvold, F.H., Levin, M.-D, Waage, A, … Abildgaard, N. (2020). Ixazomib-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial. Haematologica, 105(12), 2879–2882. doi:10.3324/haematol.2019.240374